SynthesisZeitschrift fur Rheumatologie2024
Effect of urate-lowering therapy on all-cause and CVD-specific mortality in gout and hyperuricemia: a meta-analysis.
Synthesis in Zeitschrift fur Rheumatologie, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- A metabolomic signatures in hyperuricemia: a systematic review.Metabolomics : Official journal of the Metabolomic Society · 2026Pooled it
- The efficacy and safety of different doses of febuxostat and allopurinol: A meta-analysis.Joint diseases and related surgery · 2025Pooled it
- Pooled it
- Sex differences in the associations between prior weight loss and all-cause or cardiovascular mortality in non-elderly individuals with hyperuricemia: a mortality follow-up study.Nutrition & metabolism · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to assess the relationships between urate-lowering therapy (ULT) and both all-cause and cardiovascular disease (CVD)-specific mortality in patients diagnosed with gout or hyperuricemia.
methodsThe PubMed, Embase, and Cochrane databases were thoroughly searched to gather literature on overall and/or CVD-specific hazard ratios (HRs) of patients with gout or hyperuricemia. A meta-analysis was conducted to evaluate the mortality risks of UTL users in gout or hyperuricemia populations.
resultsThis meta-analysis included 11 comparative studies encompassing 38,396 ULT users and 47,530 controls for evaluating all-cause mortality in gout or hyperuricemia. ULT treatment in patients with gout or hyperuricemia led to a significantly lower risk of all-cause mortality compared to patients not receiving ULT (HR = 0.783, 95% confidence interval [CI] = 0.702-0.874; p < 0.001). Both ULT and allopurinol were associated with decreased all-cause mortality rates (ULT HR = 0.651, 95% CI = 0.520-0.816; p < 0.001; allopurinol HR = 0.836, 95% CI = 0.731-0.957; p = 0.009). ULT initiation significantly reduced CVD-specific mortality in hyperuricemia patients, although the same was not observed in gout patients (HR for hyperuricemia = 0.872, 95% CI = 0.796-0.955; p = 0.003; HR for gout = 0.676, 95% CI = 0.296-1.544; p = 0.353).
conclusionThis meta-analysis indicates that ULT substantially reduces all-cause mortality in patients with gout or hyperuricemia, although allopurinol does not significantly affect CVD-specific mortality. These results underscore the potential of ULT for enhancing survival rates in special patient populations.
Indexed as
Identifiers
39636389What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.